sveSVENSKA   |   polPOLSKI   |   engENGLISH

+48 12 42 25 850 (Cracow) / +46 8 556 063 50 (Stockholm)     LinkedIN     Twitter

Case studies

Our collaboration with the Client always starts with a thorough analysis of the possibilities of obtaining funding for the projects and investments the Client plans to undertake.

GAEU’s experts adopt an individual approach towards each project, which allows us to identify unconventional funding opportunities and draw up a project concept that will stand out from the competition. The added value of the services provided by GAEU is illustrated by the examples below.

Immunovia AB
Immunovia AB

Immunovia AB – Clinical validation of a serum protein biomarker signature for the early diagnosis of pancreatic cancer

The Outcome

Immunovia AB was granted 4,25 Meur from the Horizon 2020 SME Instrument programme, phase 2. 

The company

Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases earlier and more accurately than previously possible. 

The project

The project aims to perform the clinical validation of a serum biomarker signature for the early diagnosis of pancreatic cancer. The biomarker signature is based on the world’s most advanced recombinant antibody microarray platform owned by Immunovia AB. The underlying technology is affinity proteomics. The biomarker signature hence exploits the body’s own detection network for the diagnosis of cancer. The initial retrospective clinical studies have confirmed that the biomarker signature can accurately separate pancreatic cancer patients from healthy individuals. The implication is that the signature, once validated by a robust method, has a very high potential for the short-term uptake into clinical practice.

GAEU's role

GAEU has been deeply involved in structuring the scope and configuration of the project and its budget. GAEU conducted workshops with the client and wrote the successful SME Instrument phase 2 application. GAEU also produced the Grant Agreement and reported the project to the EC.

Testimonial

“GAEU Consulting helped us to structure our projects based on the criterias applied in the SME instrument. During a full-day workshop we discussed the application strategy and how the clinical content was to be presented. Then GAEU wrote the application and guided us through the process. The Horizon 2020 experts in GAEU proved to be very efficient and professional in their work and had great commitment and interest in our project which resulted in a grant of EUR 4.25 million for clinical validation of a biomarker for early diagnosis of pancreatic cancer. We are very pleased with GAEU Consulting's performance and we highly recommend the company for similar efforts. GAEU Consulting is an excellent advisor suited for excellent innovation projects in the Horizon 2020! “ Mats Grahn CEO, Immunovia

Mats Grahn vd

Cinnober Financial Technology AB
Cinnober Financial Technology AB

Cinnober Financial Technology AB – TRADExpress Client Clearing

The Outcome

Cinnober Financial Technology AB was granted 2,5 Meur from the Horizon 2020 SME Instrument programme, phase 2. 

The company

Cinnober Financial Technology AB develops mission-critical system solutions for exchange trading, clearing, risk management & other financial services. It offers solutions to international exchanges, clearinghouses, banks and brokerages.

The project

The project’s objectives include reducing banks’ cost of capital and collateral requirements by efficient utilization across business units and asset classes. It will also impart operational efficiencies across listed and OTC flows, resulting in a reduced cost per trade. The technology is based on Cinnober’s TRADExpress RealTime Clearing, an offering towards clearinghouses and CCPs. 

GAEU's role

GAEU has been deeply involved in structuring the scope and configuration of the project and its budget. GAEU conducted workshops with the client and wrote the successful SME Instrument phase 2 application. GAEU also produced the Grant Agreement. 

Testimonial

“We are very pleased with GAEU Consulting's work! Together with GAEUs advisors, we have managed to win in fierce competition with other European companies. This is the result of a focused interaction between Cinnober and GAEU which resulted in a SME Instrument phase 2 grant of EUR 2.5 million for a pioneering project in client clearing for international banks.” Veronica Augustsson CEO, Cinnober

Veronica Augustsson CEO

Nelson Garden AB
Nelson Garden AB

Nelson Garden AB – the ultimate priming solution scaling up seed storability length

The Outcome

2013 Nelson Garden AB was granted 200,000 eur from the Swedish Innovation Agency Vinnova for conducting R&D activities. 2016 Nelson Garden was granted 1,2 Meur from the Horizon 2020 SME Instrument programme, phase 2.

The company

With its 11,000 resellers Nelson Garden is the largest seed sales company in Scandinavia. Nelson Seed Development is an innovation and research company within the Nelson Garden Group. Seed Vitalisation® is an ecological and fully automated seed priming process, developed and patented by Nelson Seed Development. It can rightfully be expected to transform the commercial landscape of the seed industry within the near future.

The project

Nelson Garden has developed the ecological Seed Vitalisation® method, which is the first and only priming method that allows for long-term storage of primed seeds. Seeds that have been treated by Seed Vitalisation® will have all the traditional benefits of priming such as faster and more uniform germination, higher rate of germination and stronger seedlings, which altogether helps to increase the yield. The project objective is to scale up the vitalisation method and existing machine prototype to a commercially viable level and demonstrate the vitalisation method to potential customers on European markets.

GAEU's role

GAEU has been working closely with the project team from the very beginning. We begun by writing the winning R&D Vinnova application and to advise the project team when pitching the project to the grant agency. Regarding the SME Instrument funding, we have been deeply involved in deciding the scope and configuration of the project and its budget. We have conducted workshops, we wrote the successful Phase 2 application and we took care of the Grant Agreement. Along the way we also were invited to a fantastic Nelson crayfish party in the deep forests of the Småland region.

Testimonial

“We are very pleased with GAEU. The dialogue with GAEU is always constructive. The staff is always on hand to give straight answers to any questions. GAEU´s project leader Tomasz Wąsik provides very clear instructions, which is a good thing. Throughout the process we have had continuous checks and reviews, which we have appreciated. I really would like to recommend GAEU to anyone who is interested in applying for Horizon 2020 funding.” Håkan Jalling, EU Project Manager

Håkan Jalling EU project manager

OPSIS AB
OPSIS AB

Development and demonstration of an innovative FT-NIR-based system for food content analysis

The Outcome

OPSIS AB was granted 2,3 Meur from the Horizon 2020 SME Instrument programme, phase 2. 

The company

OPSIS AB is a globally present company that develops, manufactures and markets state-of-the-art, innovative systems for gas analysis and process control.

The project

Opsis´project aims to develop and demonstrate a system for qualitative food content analysis in liquid food samples, based on a highly innovative method. With the superior precision and versatility of analysis offered by our patented solution our product will open up new possibilities for food and beverage producers to have a complete control of their production process at any time, thus ensuring the highest standards in food quality and safety as well as reducing costs and increasing their efficiency in production.

GAEU's role

GAEU has been deeply involved in structuring the scope and configuration of the project and its budget. GAEU conducted workshops with the client and wrote the successful SME Instrument phase 2 application. GAEU also produced the Grant Agreement. 

Testimonial

“Last year we asked GAEU Consulting to find a funding scheme that could help us to be ready with a new innovation, a contribution large enough to make a difference to our business. GAEU recommended phase 2 of the SME instrument and has since written the application and guided us through the process; workshops, assistance with application strategies and guidance on what information should be supplemented. We applied for the first-time last spring. The application passed the threshold but received no grants due to competition from other companies. GAEU analyzed the situation, gave us valuable feedback from the result and recommended us to reapply, which not only led to improvement of the project but also resulted in a grant of EUR 2.3 million for development of a new solution for analysis in the food industry. We strongly recommend GAEU! We will use them in the future.” Svante Wallin, CEO OPSIS

Svante Wallin, CEO OPSIS AB - Olle Lundström, Director OPSIS LiquidLINE divisionen

Betagenon AB

Betagenon AB -  AMPK-DIAB, a small molecule AMP activated protein kinase (AMPK) activator, denoted O304, as a novel innovative drug for the treatment of type 2 diabetes

The Outcome

Betagenon was granted 1,8 Meur from the Horizon 2020 SME Instrument programme, phase 2. 

The company

Betagenon is a biotechnology company focused on the development of AMP-activated protein kinase (AMPK) activator compounds to treat chronic energy balance disorders diseases in metabolically challenged elderly and/or obese individuals. Drugs that activate AMPK are expected to have beneficial effects on metabolic and cardiovascular diseases and on certain cancers. 

The project

This project aims to close the gap to the market for a small molecule AMP activated protein kinase (AMPK) activator, denoted O304, as a novel first-in-class drug for the treatment of type 2 diabetes (T2D) and associated cardiovascular complications, including heart failure and peripheral arterial disease. The number of adults around the world with diabetes quadrupled from 108 million in 1980 to 422 million in 2014. None of the existing drugs, however, reduces insulin resistance - a primary cause of obesity-induced T2D. Betagenon has developed and pre-validated the first candidate AMPK activator drug in T2 diabetics, a key regulator of energy balance, both on a single cell level and the whole organism level. The project is strategically focused on performing a Phase II proof-of-concept validation of O304.

GAEU's role

GAEU has been deeply involved in structuring the scope and configuration of the project and its budget. GAEU conducted workshops with the client and wrote the successful SME Instrument phase 2 application. GAEU also produced the Grant Agreement and reported the project to the EC. 

Testimonial

“In the application process, GAEU Consulting has proven itself to be a first class life science advisor, showing excellent understanding of our candidate drug and forces driving commercialization of medicinal products. GAEU has taken the leading role in shaping strategies behind our proposal, which resulted in the total scoring of 14.64 out of 15 – an almost perfect proposal. Based on my experience in cooperating with GAEU, I strongly recommend them as Horizon 2020 advisors.” Thomas Edlund, Ph.D., Prof. Founder, Chief Executive Officer.

Thomas Edlund Ph.D., Prof. Founder, Chief Executive Officer

Corline Biomedical AB

Corline Biomedical AB – Renaparin,  improving kidney transplantation outcome with Renaparin® for patients with End-Stage Renal Disease by attenuating graft ischemia reperfusion injury

The Outcome

Coreline was granted 2,3 Meur from the Horizon 2020 SME Instrument programme, phase 2. 

The company

Corline, founded in 1991, develops, manufactures and markets heparin based solutions to improve kidney transplantation, cell therapies and applications in the evolving field of regenerative medicine. Using the same heparin technology platform - CHC™ - Corline also provides best-in-class surface coatings, making medical device implants blood and biocompatible.

The project

This project will validate the safety and efficancy of Corline Biomedical’s pharmaceutical compound Renaparin®, a novel cell replacement technology used to coat the lining of the blood vessels of kidneys prior to transplantation. Donor kidneys lack natural blood flow while awaiting transplantation. This can lead to ischemia (a shortage of oxygen and glucose supply to the kidney tissue). Renaparin® is used when the kidney has been extracted from the donor and is stored in preservation solution awaiting transplantation. There, it binds to, replaces, repairs and protects damaged kidney cells on the endothelium of the vascular wall. As a result, a kidney is less likely to activate the host’s innate immune system, which increases the chances of organ survival and substantially reduces the likelihood of organ rejection. The activities proposed in this project will bring Renaparin® through a Phase I/IIa clinical trial in humans.

GAEU's role

GAEU has been deeply involved in structuring the scope and configuration of the project and its budget. GAEU conducted workshops with the client and wrote the successful SME Instrument phase 2 application. GAEU also produced the Grant Agreement and reported the project to the EC. 

Testimonial

“This is absolutely fantastic for Corline! This grant is one of the highest allocations awarded to a Swedish life science company within SME Instrument and it will allow us to fully fund our entire clinical study on Renaparin®. Apart from the purely practical and economic implications, it is also a great recognition of our project. It is really encouraging that the European Commission has recognized the potential in our project. With this grant, we will be able to create a platform from which we can accelerate Corline’s growth in kidney transplantation and new indications. GAEU Consulting has been our advisor throughout the entire application process and wrote our grant application. The outstanding application scoring received is proof to the quality of their service. I highly recommend GAEU as Horizon 2020 advisors for Life Science companies.” Henrik Nittmar, PhD CEO

Henrik Nittmar PhD CEO

SenzaGen AB

SenzaGen AB -  GARDair, the first predictive in vitro assay for the identification of respiratory sensitizers

The Outcome

SenzaGen AB was granted 2,4 Meur from the Horizon 2020 SME Instrument programme, phase 2. 

The company

SenzaGen AB is a privately-owned Biotech-company, providing methods for assessment of immunotoxicological properties of chemical compounds and mixtures. Continuous R&D activities aims to broaden the application domain of provided services, and the company have close connections to immunological and toxicological researchers at Lund University, Sweden.

The project

The GARDair project will optimize and validate the first predictive assay for respiratory sensitization and bring it to market. This innovative in vitro test builds on the successes of its forerunner – the GARDskin assay, which has been shown to hold the highest predictive power (89%) of skin sensitizers amongst all commercially available methods. The GARD technology offers an unparalleled way to make hazard predictions, as it uses a human dendritic cell line to monitor immunological responses to chemical exposure. If successful, the project will allow SenzaGen to become a key player in any application of animal-free, cell-based systems, aiming to assess sensitization capabilities of various compounds and to fully realize its business development strategy.

GAEU's role

GAEU has been deeply involved in structuring the scope and configuration of the project and its budget. GAEU conducted workshops with the client and wrote the successful SME Instrument phase 2 application. GAEU also produced the Grant Agreement.

Testimonial

“At SenzaGen, we have strong ambitions to grow and enable animal-free, cell-based systems to assess hazards and potency of industrial compounds. The grant we have received will be the perfect catalyst for this vision. We will use the funding to bring an innovative product to the market, with potential to become the cornerstone of our long-term competitiveness. For a small life science company, a grant covering 100 % of the project costs is of unparalleled value. We would like to thank GAEU for supporting us to secure this grant. We have received excellent guidance and advice in the application process. The team responsible for our proposal was easy to work with and very knowledgeable. GAEU is an excellent Horizon 2020 advisor and long term business partner.” Anki Malmborg Hager CEO

Anki Malmborg Hager CEO

Clinical Laserthermia Systems AB
Clinical Laserthermia Systems AB

Clinical Laserthermia Systems AB (CLS) – Clinical validation and commercialization of innovative immunostimulating Interstitial Laser Thermotherapy

The Outcome

CLS was granted 2,1 Meur from the Horizon 2020 SME Instrument programme, phase 2.  

The company

Clinical Laserthermia Systems AB is a Lund-based company active in the medical equipment industry active since 2006. The Company develops and markets a product for the treatment of solid cancer tumors. The product is based on Immunostimulating Laser Thermo Therapy (imILT). 

The project

The project will bring the groundbreaking immunostimulating Interstitial Laser Thermotherapy (imILTCLS) to the market and clinical practice. This minimally invasive therapy is designed to achieve local tumour destruction and stimulate specific antitumour immunity in a patient’s body. In recent years, anti-cancer therapies based on activation of the immune system have grown in significance and popularity. This approach is especially viable for patients who previously had very few treatment options. However, only approx. 20 % of all patients respond to drug-based immunotherapies of today. The project is aimed at delivering a novel device-based cancer immunotherapy method that destroys the tumour locally and induces long-lasting, vaccination-like, systemic immunity against the treated form of cancer. 

GAEU's role

GAEU has been deeply involved in structuring the scope and configuration of the project and its budget. GAEU conducted workshops with the client and wrote the successful SME Instrument phase 2 application. GAEU also produced the Grant Agreement and reported the project to the EC. 

Testimonial

“We are very pleased to be granted Horizon 2020 funding. This significant amount of money, EUR 2.1, will be spent on the validation of imILTCLS. The studies will be performed in collaboration with hospitals we have an established relationship with: in Marseille, France, Porto, Portugal and in Nottingham, the UK. The grant gives us stronger resources to bring imILTCLS to the market and to offer our method as an option in cancer treatment.” Lars-Erik Eriksson, CEO CLS

CEO Lars-Erik Eriksson

Vibrosense Dynamics AB

VibroSense Dynamics AB – Innovative diagnostic device for the early detection of diabetic neuropathy in diabetes patients

The Outcome

Vibrosense Dynamics AB was granted 50 Keur from the Horizon 2020 SME Instrument programme, phase 1. 

The company

VibroSense Dynamics AB is focused on providing efficient systems for early detection and diagnosis of peripheral sensory neuropathy, i.e. disease of large nerve fibers and nerve trunks in the legs and arms.

The project

The objective of the innovation project was to develop and clinically validate the first diagnostic device for the early detection of diabetic neuropathy (also referred to as diabetic foot). Diabetic foot is a common complication of both type 1 and type 2 diabetes. Current methods are only able to detect diabetic foot once the patient is already experiencing loss of sensation. This can result in an increased number of amputations and costs as a result of those amputations. 

GAEU's role

GAEU has been deeply involved in structuring the scope and configuration of the project and its budget. GAEU conducted workshops with the client and wrote the successful SME Instrument phase 1 application. GAEU also produced the Grant Agreement.

Testimonial

“The money will be used to analyze the market and develop a solid business plan. Result: a grant of EUR 50 000 for a Horizon SME Instrument phase 1 pre-study, now working with GAEU with a phase 2 application.” Toni Speidel CEO, Vibrosense Dynamics

Toni Speidel CEO

Watty AB
Watty AB

Watty AB - Innovative energy management technology for smart energy decisions

The Outcome

Watty AB was granted 50 Keur from the Horizon 2020 SME Instrument programme, phase 1. 

The company

Watty AB build ground-breaking solutions that make it possible for anyone to understand complex energy data. Watty AB´s product aims to bring the world's energy data online and empower people to make smarter decisions.

The project

Watty can pin-point the smartest way to save energy in any home with just a single piece of low-cost hardware. Our innovative technology analyses the total energy use in a household and breaks it down into its components, i.e. the energy use per appliance. The technology deciphers a distinctive behaviour and usage pattern for every appliance and is thus able to diagnose the entire energy usage of a household in detail. The implementation of this technology will for the first-time permit households to make concrete, smart energy saving decisions based on detailed data about the real-time usage of their appliances. As this can help households save 10-30% of their energy use, it will both help the users to reduce costs, while at the same time make a large contribution to the EU objective of a 20% energy saving by 2020. 

GAEU's role

GAEU has been deeply involved in structuring the scope and configuration of the project and its budget. GAEU conducted workshops with the client and wrote the successful SME Instrument phase 1 application. GAEU also produced the Grant Agreement. 

Testimonial

“There is more energy to save in our homes than in the rest of the society. Wattys device figures out which appliances that are energy thieves. Everything is done automatically, allowing consumers to easily understand where there is energy and money to save. GAEU Consulting wrote our EU application to Horizon 2020 and guided us methodically through the application process which resulted in a grant of EUR 50 000 for a pre-study. We are very pleased with GAEU Consulting's efforts and recommend the company for similar services.” Hjalmar Nilsonne CEO, Watty

Hjalmar Nilsonne vd

Boule Medical AB

Boule Medical AB – Innovative 5-part haematology analyser for near-patient diagnostics

The Outcome

Boule Medical AB was granted 50 Keur from the Horizon 2020 SME Instrument programme, phase 1. 

The company

Boule Medical AB manufactures hematology analyzers, mixers, blood controls, and reagents. The company was founded in 1969 and is based in Stockholm.

The project

The project was aimed at developing and validating the first Complete Blood Cell Count (CBC) haematology analyser including 5-part differential and reticulocytes (5-part analyser) for the decentralized, low-volume testing haematology market. Today, CBC tests are performed using either 3-part or 5-part analysers. The latter are growing in importance worldwide as they are able to provide much more detailed information about the medical condition of the patient. However, 5-part analysers are currently designed entirely for the high-volume testing market with complex, centralized laboratories equipped with large sample automation devices. 

GAEU's role

GAEU has been deeply involved in structuring the scope and configuration of the project and its budget. GAEU conducted workshops with the client and wrote the successful SME Instrument phase 1 application. GAEU also produced the Grant Agreement. 


Degoo Backup AB

Degoo Backup AB – the first back-up service based on dynamic routing of transfer data to data centres

The Outcome

Degoo Backup AB was granted 50 Keur from the Horizon 2020 SME Instrument programme, phase 1. 

The company

Degoo Backup AB is an innovative Swedish start-up established in 2012 to propose a fresh approach to cloud backup services. The company was created by individuals with extensive knowledge and experience in ICT technologies, programming, cloud-based services and business development. To date, Degoo has attracted more than 4 million users. Degoo backup is the most affordable backup in the world. 

The project

This innovation project will create Degoo Backup, a novel cloud backup service that will redefine the established business model on the international cloud backup market. The idea is to create the service that breaks the monopolized position of the multinational players, such as Google, Amazon, Microsoft or Apple, by changing their status from the players that control the market for cloud infrastructure as a service (IaaS) and thus dictate cloud backup prices to providers of storage space that have to compete with smaller and national players. This will be enabled though a novel functionality for dynamic, rule-based distribution of data to the data centres where the data is stored.

GAEU's role

GAEU has been deeply involved in structuring the scope and configuration of the project and its budget. GAEU conducted workshops with the client and wrote the successful SME Instrument phase 1 application. GAEU also produced the Grant Agreement. 

Testimonial

“I am impressed with the professional work that GAEU has done for us. They have really helped us in pinpointing the most relevant arguments.” Carl Hasselskog, CEO Degoo Backup AB

Carl Hasselskog CEO

Bone Support AB

BONE SUPPORT AB - A novel bone implant with enhanced bone healing capacity

The Outcome

Bone Support AB was granted 50 Keur from the Horizon 2020 SME Instrument programme, phase 1.

The company

Bone Support AB is a Scandinavian medical technology company dedicated to the development of injectable osteoconductive biomaterials for the treatment of fragility fractures caused by osteoporosis, and bone voids or gaps caused by trauma, disease or related to surgical procedures.

The project

The objective of the project was to bring the first bone implant with enhanced bone healing capacity to the market and clinical practice. The market demand for bone implants is steadily increasing driven by aging populations, increased demand for high quality of life and an increasing number of joint reconstruction surgeries. Enhancement of the bone healing process is often necessary, especially for patients with larger bone voids and gaps.

GAEU's role

GAEU has been deeply involved in structuring the scope and configuration of the project and its budget. GAEU conducted workshops with the client and wrote the successful SME Instrument phase 1 application. GAEU also produced the Grant Agreement. 


Arocell AB

AroCell AB - universal serum protein biomarker for cancer screening, diagnosis, treatment response monitoring and early detection of relapse

The Outcome

AroCell AB was granted 50 Keur from the Horizon 2020 SME Instrument programme, phase 1. 

The company

AroCell AB was founded in 2003. The company is located in Uppsala, Sweden and develops and commercializes tests that can be used in the prognosis, monitoring and follow-up of cancer.

The project

The project is a feasibility study for TK210 ELISA – a serum and plasma biomarker for cancer diagnosis and treatment response. Leveraging on the knowledge that cancer cells undergoing rapid growth produce and release into the blood abnormal amounts of protein called thymidine kinase (TK), AroCell has pre-validated a biomarker that quantifies the amount of TK protein directly in the serum in a blood sample. Current cell growth-related biomarkers are measured from tumour tissue, which limits their clinical utility. Recognizing a strong business opportunity, AroCell will propose TK210 ELISA as an easily-deployable and cost-efficient diagnostic and treatment-response test.

GAEU's role

GAEU has been deeply involved in structuring the scope and configuration of the project and its budget. GAEU conducted workshops with the client and wrote the successful SME Instrument phase 1 application. GAEU also produced the Grant Agreement.